We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
The investor discussions surrounding Oxford Biomedica Plc (OXB) have centered on the company's recent developments and the overarching sentiment regarding its strategic position within the biopharmaceutical sector. A significant highlight from these conversations is the ongoing speculation around potential bids from larger players, likely aimed at bolstering their manufacturing capabilities. A contributor pointed out the interesting dynamics at the AGM, suggesting that there was a "feeling of potential vulnerability to an opportunistic bid," emphasizing that OXB's small-cap status may render it susceptible to acquisition attempts by mega-cap firms. The discussions reflect a broader concern among investors about OXB's share price performance and its positioning amid competitive pressures within the cell and gene therapy contract development and manufacturing organization (CDMO) space.
Financially, investors noted that OXB has projected sales of approximately £180 million for the upcoming year, which may signal a robust recovery plan after challenging periods. Several quotes echoed investor sentiment on this topic, with one user stating, "a record revenue year" could substantially enhance the company's valuation. Others provided mixed predictions for share price targets, with estimates ranging from £5.50 to as high as £10 over the next year, reflecting differing levels of optimism about OXB's ability to leverage its capabilities under current market conditions. Overall, the sentiment appears cautious yet hopeful, with a significant focus on upcoming strategic decisions and events, such as potential partnerships or acquisitions that could reshape the company’s trajectory.
Show more
Oxford Biomedica Plc (OXB) announced in a recent update that as of November 30, 2024, its issued share capital consists of 105,938,933 ordinary shares, with no shares held in treasury. This figure is important for shareholders as it serves as the denominator for calculating their obligations under the FCA's Disclosure Guidance and Transparency Rules regarding notifications of interest or changes in their interest in the company.
This announcement signals OXB's ongoing compliance with regulatory requirements as a public company while also providing shareholders with key information necessary for their governance and investment decisions. The company continues to focus on expanding its capabilities in the cell and gene therapy sectors, aiming to leverage its infrastructure for growth in the competitive market landscape.
Show more
I'm more than happy with my OXB investment the management are switched on and the future looks positive. I hedged my position in Cambridge Cognition with OXB and that has proved worthwhile. In the long term both busineses being great examples of business at its best and creating employment for highly educated graduates |
Gareth, don't believe snide comments from people who have a long history of looking down on and criticising other people's efforts whilst lazily contributing sfa themselves. |
Gareth don't believe some of the hype spouted here just leads to disappointment |
No 7am RNS ahead of todays presentation at 10am, Jeffries Conference. |
Dom, |
If only there were a treatment to stop a share dropping 4% in half an hour with no news at all? |
I wasn't trying to trash it Super (if it read that way) but I'm guessing we agree that the currently secret commercial CAR-T multiple myeloma deal (or similar) is far more relevant to us as Cabaletta have nothing anywhere near a registration trial endpoint. |
For the 3 SLE patients there's only one Grade 1 AE, which is pretty minimal. The LN patient didn't do as well in that regard, but seems to have started off really ill, and ended up much better - zero immunosuppressants, and steroids in continuing taper. Her own testimony is highly positive, on slide 23. I think they'll be very happy with those lupus results. |
Not a doctor PB but it started off with perfect safety data, whereas now they seem to have events in SLE (see slide 16) |
More positive news from Cabaletta HTTps://www.linkedin |
Xoptimist, |
I think Colin Bond is a fantastic, high calibre appointment to the board who brings with him a wealth of experience in pharma; finance; audit; international deal making and who will almost certainly be a useful sounding board and advisor to Frank and his team. |
Does it help being a former pharmacist or involved in biotech during your career when appointed to an audit committee? |
My heart skipped a beat, then I read that We’ve made a change in the audit committee. |
...and YOUR theory icejelly? Oh. You don't know nuffink! |
Does this high volume, low price movement fit in with Harry's theory? If not, it will fit in with one of his other theories I'm sure. |
Best part of 400k today. These are big volumes for very small price movement. |
Positive update from Kyverna HTTps://www.linkedin |
Trump appointment has created a few concerns for us and some nervy small scale selling so we are in a little drift mode. Not for long we hope, surely punters are not waiting on the trading bot to buy back in :) |
Be grateful that OXB is no longer involved in vaccines.Moderna has fallen 80% in six months to stand at a low of just $39 compared to a high of around $450 during Covid.Sentiment clearly effected by Mr Robert Kennedy's appointment. Albeit OXB won't be in the firing line,it could suffer a touch of 'collateral damage' as Kennedy roughs up drug companies but the appreciation that the company is moving into profit is more than likely to eclipse concerns. |
Re Jefferies I would say at the very least an updated corporate presentation and maybe revised forecast for next year. This plus hopefully the JPM conference at the beginning of next year would be two big audiences to set out the coming year to. |
Didn't expect to back in the 3's this morning. |
85 shares in half an hour and another big price movement on the back of it? |
London Healthcare Conference, the largest healthcare dedicated conference in Europe. OXB CEO and CFO presenting,attending with the presentation available to investors via the website. I don't think they will be revealing bad news? |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions